Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192377881> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3192377881 abstract "Abstract MAFB is a transcription factor specifically expressed in macrophages. Using in vitro and in vivo in mouse tumor models, our previous study suggested that MAFB could be a suitable marker for tumor-associated macrophages (TAMs), besides MAFB is expressed in anti-inflammatory alternatively activated M2 macrophages in vitro. TAMs play a key role in the tumor microenvironment (TME) by inducing immunosuppression, angiogenesis, tumor invasion, and metastasis. However, finding a suitable specific biomarker and target for TAMs is challenging. Here, we demonstrated that MAFB could be used as a biomarker for TAMs and consequently, for severity in various human cancers, including lung, liver, colon, and pancreatic cancers, according to the immunohistochemical analysis of the expression of MAFB, CD68, and CD204. Moreover, In a cohort of lung adenocarcinomas patients (n = 120), increased MAFB expression was related to increased tendency towards metastasis and poor overall survival rate. Further, we showed that MAFB expression was positively correlated to the expression of CD204 and CD68 in both human hepatocarcinoma and colon cancers. Our findings indicate that MAFB as a specific biomarker can be used as prognostic marker for Metastasis potential in Lung adenocarcinomas patients and also a biomarker for the severe Liver, Colon and pancreatic cancers. In addition, we showed that MAFB was expressed in Tumor associated macrophages expressing Programmed cell death protein-1 and/or Programmed cell death ligand 1 (TAM PD-1+ and TAM PD-L1+) cells in both human lung adenocarcinomas and Lewis lung carcinoma (LLC) mouse model. These findings indicate that MAFB can be a potential target for drug development against TAM PD-1+ and TAM PD-L1+ cells. In summary, transcriptional factor MAFB can be used as a specific biomarker, prognostic marker and a potential target for cancer immunotherapy against TAMs." @default.
- W3192377881 created "2021-08-16" @default.
- W3192377881 creator A5010211818 @default.
- W3192377881 creator A5036614400 @default.
- W3192377881 creator A5051030521 @default.
- W3192377881 creator A5069126737 @default.
- W3192377881 creator A5076388932 @default.
- W3192377881 creator A5076782173 @default.
- W3192377881 creator A5086988341 @default.
- W3192377881 date "2021-08-05" @default.
- W3192377881 modified "2023-09-27" @default.
- W3192377881 title "MAFB is a biomarker for cancer severity, prognostic marker, and a potential target for cancer immunotherapy" @default.
- W3192377881 doi "https://doi.org/10.21203/rs.3.rs-763431/v1" @default.
- W3192377881 hasPublicationYear "2021" @default.
- W3192377881 type Work @default.
- W3192377881 sameAs 3192377881 @default.
- W3192377881 citedByCount "0" @default.
- W3192377881 crossrefType "posted-content" @default.
- W3192377881 hasAuthorship W3192377881A5010211818 @default.
- W3192377881 hasAuthorship W3192377881A5036614400 @default.
- W3192377881 hasAuthorship W3192377881A5051030521 @default.
- W3192377881 hasAuthorship W3192377881A5069126737 @default.
- W3192377881 hasAuthorship W3192377881A5076388932 @default.
- W3192377881 hasAuthorship W3192377881A5076782173 @default.
- W3192377881 hasAuthorship W3192377881A5086988341 @default.
- W3192377881 hasBestOaLocation W31923778811 @default.
- W3192377881 hasConcept C121608353 @default.
- W3192377881 hasConcept C126322002 @default.
- W3192377881 hasConcept C142724271 @default.
- W3192377881 hasConcept C203014093 @default.
- W3192377881 hasConcept C204232928 @default.
- W3192377881 hasConcept C2776107976 @default.
- W3192377881 hasConcept C2776256026 @default.
- W3192377881 hasConcept C2776460901 @default.
- W3192377881 hasConcept C2777701055 @default.
- W3192377881 hasConcept C2779013556 @default.
- W3192377881 hasConcept C2781197716 @default.
- W3192377881 hasConcept C3020616263 @default.
- W3192377881 hasConcept C502942594 @default.
- W3192377881 hasConcept C55493867 @default.
- W3192377881 hasConcept C71924100 @default.
- W3192377881 hasConcept C86803240 @default.
- W3192377881 hasConceptScore W3192377881C121608353 @default.
- W3192377881 hasConceptScore W3192377881C126322002 @default.
- W3192377881 hasConceptScore W3192377881C142724271 @default.
- W3192377881 hasConceptScore W3192377881C203014093 @default.
- W3192377881 hasConceptScore W3192377881C204232928 @default.
- W3192377881 hasConceptScore W3192377881C2776107976 @default.
- W3192377881 hasConceptScore W3192377881C2776256026 @default.
- W3192377881 hasConceptScore W3192377881C2776460901 @default.
- W3192377881 hasConceptScore W3192377881C2777701055 @default.
- W3192377881 hasConceptScore W3192377881C2779013556 @default.
- W3192377881 hasConceptScore W3192377881C2781197716 @default.
- W3192377881 hasConceptScore W3192377881C3020616263 @default.
- W3192377881 hasConceptScore W3192377881C502942594 @default.
- W3192377881 hasConceptScore W3192377881C55493867 @default.
- W3192377881 hasConceptScore W3192377881C71924100 @default.
- W3192377881 hasConceptScore W3192377881C86803240 @default.
- W3192377881 hasLocation W31923778811 @default.
- W3192377881 hasOpenAccess W3192377881 @default.
- W3192377881 hasPrimaryLocation W31923778811 @default.
- W3192377881 hasRelatedWork W2364224162 @default.
- W3192377881 hasRelatedWork W2387966709 @default.
- W3192377881 hasRelatedWork W2908335280 @default.
- W3192377881 hasRelatedWork W3029904812 @default.
- W3192377881 hasRelatedWork W3173207637 @default.
- W3192377881 hasRelatedWork W4223644646 @default.
- W3192377881 hasRelatedWork W4312075079 @default.
- W3192377881 hasRelatedWork W4360869587 @default.
- W3192377881 hasRelatedWork W4381377675 @default.
- W3192377881 hasRelatedWork W4381470058 @default.
- W3192377881 isParatext "false" @default.
- W3192377881 isRetracted "false" @default.
- W3192377881 magId "3192377881" @default.
- W3192377881 workType "article" @default.